Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.63
+0.33 (2.02%)
At close: Nov 3, 2026, 4:00 PM EST
15.68
-0.95 (-5.73%)
After-hours: Nov 3, 2026, 7:56 PM EST
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,371 employees as of December 31, 2025. The number of employees increased by 77 or 5.95% compared to the previous year. That makes Ultragenyx Pharmaceutical the 12,669th largest employer in the world and 1,983rd in the United States.
Employees
1,371
Change (1Y)
77
Growth (1Y)
5.95%
Revenue / Employee
$532,458
Profits / Employee
-$382,203
Market Cap
1.63B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,371 | 77 | 5.95% |
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| uniQure | 221 |
| Stoke Therapeutics | 170 |
| Maze Therapeutics | 141 |
RARE News
- 10 hours ago - Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2026 - Transcripts
- 10 hours ago - Ultragenyx Pharmaceutical Earnings release: Q3 2026 - Filings
- 11 hours ago - Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 - GlobeNewsWire
- 7 days ago - Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update - GlobeNewsWire
- 20 days ago - Ultragenyx initiated with a Neutral at UBS - TheFly
- 20 days ago - Ultragenyx to sell Rare Pediatric Disease PRV for $203M - TheFly
- 20 days ago - Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million - GlobeNewsWire
- 20 days ago - Ultragenyx Pharmaceutical Slides: Corporate presentation - Filings